Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Antiviral Therapy|May 12, 2004
Asymptomatic hyperlactataemia: predictive value, natural history and correlatesGrace A McComsey, Linda Yau
BMJ Open Ophthalmology|November 22, 2019
Clinically meaningful visual improvements and predictors of early vision gains with ranibizumab for diabetic macular oedemaLawrence Morse, Linda Yau, Lisa Tuomi
Ophthalmology|January 16, 2014
Time to clinically significant visual acuity gains after ranibizumab treatment for retinal vein occlusion: BRAVO and CRUISE trialsAllen B Thach, Linda Yau, Carol Hoang, et al.
Retina (Philadelphia, Pa.)|July 22, 2014
Collateral vessel presence in branch and central retinal vein occlusions and their impact on visual acuity and anatomical gains: a retrospective analysisRishi P Singh, Tamara J Lee, Linda Yau, et al.
Ophthalmology|July 26, 2014
Monthly versus as-needed ranibizumab injections in patients with retinal vein occlusion: the SHORE studyPeter A Campochiaro, Charles C Wykoff, Michael Singer, et al.
Ophthalmology|February 4, 2012
Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trialJeffrey S Heier, Peter A Campochiaro, Linda Yau, et al.
HIV Clinical Trials|December 4, 2010
A pilot study of abacavir/lamivudine and raltegravir in antiretroviral-naïve HIV-1-infected patients: 48-week results of the SHIELD trialBenjamin Young, Thanes Vanig, Edwin Dejesus, et al.
Clinical Pharmacology and Therapeutics|October 20, 2019
Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the ProductMartin Vanderlaan, Aristides Maniatis, Robert Olney, et al.
HIV Clinical Trials|June 13, 2008
Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot studyRichard Elion, Edwin Dejesus, Michael Sension, et al.
HIV Clinical Trials|December 4, 2010
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trialCalvin Cohen, Edwin Dejesus, Anthony Lamarca, et al.
Pageof 2